Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Izalontamab brengitecan - Bristol-Myers Squibb

Next Previous
X
Search
Drug Profile

Izalontamab brengitecan - Bristol-Myers Squibb

Alternative Names: BL-B01D1; BMS-986507

Latest Information Update: 02 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sichuan Baili Pharmaceutical; SystImmune
  • Developer Bristol-Myers Squibb; Sichuan Baili Pharmaceutical; SystImmune
  • Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HER2 negative breast cancer; Nasopharyngeal cancer; Non-small cell lung cancer; Small cell lung cancer; Squamous cell cancer
  • Phase II Cervical cancer; Colorectal cancer; Gastric cancer; Glioblastoma; Oesophageal cancer; Solid tumours; Triple negative breast cancer; Urogenital cancer
  • Phase I Gastrointestinal cancer

Most Recent Events

  • 30 Dec 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Combination therapy) in USA (IV) (NCT06618287)
  • 17 Oct 2024 Phase-II clinical trials in Glioblastoma (Second-line therapy or greater) in China (IV) (NCT06598787)
  • 01 Oct 2024 Bristol-Myers Squibb plans a phase I/II trial for Lung cancer (Late-stage disease, Combination therapy) in USA, Canada, Australia, Netherlands, Spain, United Kingdom (IV) (NCT06618287)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top